BioLineRx Reports First Quarter 2019 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to BioLineRx Reports First Quarter 2019 Financial Results and Provides Corporate Update

BioLineRx (BLRX) Misses Q1 EPS by 1c

May 14, 2019 7:08 AM EDT

BioLineRx (NASDAQ: BLRX) reported Q1 EPS of ($0.06), $0.01 worse than the analyst estimate of ($0.05).

"As we progress through 2019, we are approaching important data milestones with our lead program, the CXCR4 antagonist BL-8040, in two cancer indications with high unmet medical need," said Philip Serlin, Chief Executive Officer of BioLineRx. "In pancreatic cancer, an... More